propanidid

Propanidid is an ultra short–acting, nonbarbiturate intravenous general anesthetic of the phenylacetate class. It was introduced by Bayer in 1963 for rapid induction and maintenance of anesthesia of short duration. Propanidid acts primarily as a positive allosteric modulator and agonist at the gamma–aminobutyric acid type A (GABAA) receptor, enhancing inhibitory neurotransmission in the central nervous system. Its use was discontinued shortly after introduction due to reports of severe anaphylactic reactions, which were later debated to be possibly related to its solubilizer (Cremophor EL) rather than the drug itself[1][2][3][4][6].

Brand names

EpontolSombrevinFabontalFabantol

Other names

propanididopropanididumpropanidide